Tax-withholding share sale by Artivion (AORT) SVP Stanton Marshall

Rhea-AI Filing Summary

Artivion, Inc. senior vice president Stanton Marshall S. reported an automatic sale of 1,513 shares of common stock at an average price of $38.0249 per share. According to the filing, the shares were sold upon vesting of restricted stock units solely to cover tax withholding obligations and were not a discretionary trade. After this transaction, he directly holds 40,408 shares of Artivion common stock.

Insider Trade Summary

Net Seller: 1,513 shares ($57,532)

Net Sell 1 txn

Insider Stanton Marshall S.

Role SVP, Clinical & MD Affair

Sold 1,513 shs ($58K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,513	$38.0249	$58K

Holdings After Transaction: Common Stock — 40,408 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stanton Marshall S.

(Last) (First) (Middle)

1655 ROBERTS BLVD., NW

(Street)

KENNESAW GA 30144

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARTIVION, INC. [ AORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Clinical & MD Affair

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		S		1,513(1)	D	$38.0249	40,408	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction.

Remarks:

	/s/ Marshall Stanton	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Artivion (AORT) executive Stanton Marshall report in this Form 4?

Stanton Marshall reported the sale of 1,513 Artivion common shares. The shares were sold automatically upon restricted stock unit vesting to cover tax withholding obligations and were not a discretionary open-market trade.

How many Artivion (AORT) shares did Stanton Marshall sell and at what price?

He sold 1,513 Artivion common shares at an average price of $38.0249 per share. The sale was executed as a “sell to cover” transaction tied to restricted stock unit vesting for tax withholding.

Why were Stanton Marshall’s Artivion (AORT) shares sold in this transaction?

The filing states the shares were sold to pay tax withholding obligations from vesting restricted stock units. It describes the transaction as a “sell to cover” and clarifies it does not represent a discretionary decision to sell shares.

How many Artivion (AORT) shares does Stanton Marshall own after this Form 4 transaction?

After the transaction, Stanton Marshall directly owns 40,408 Artivion common shares. This post-transaction balance reflects the automatic sale of 1,513 shares used to satisfy tax withholding requirements tied to restricted stock unit vesting.

What is Stanton Marshall’s role at Artivion (AORT) mentioned in the Form 4?

Stanton Marshall is identified as an officer of Artivion, serving as SVP, Clinical & MD Affair. The Form 4 records his ownership and the tax-related share sale associated with restricted stock unit vesting.